Braun Stacey Associates Inc. Sells 16,367 Shares of Corcept Therapeutics Incorporated $CORT

Braun Stacey Associates Inc. cut its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 5.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 264,297 shares of the biotechnology company’s stock after selling 16,367 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Corcept Therapeutics were worth $9,198,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in CORT. Advisory Services Network LLC purchased a new stake in shares of Corcept Therapeutics in the third quarter worth about $25,000. Clearstead Advisors LLC boosted its position in shares of Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 193 shares during the period. Hantz Financial Services Inc. grew its stake in Corcept Therapeutics by 598.5% during the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 395 shares in the last quarter. Larson Financial Group LLC grew its stake in Corcept Therapeutics by 2,326.3% during the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 442 shares in the last quarter. Finally, Gould Capital LLC increased its holdings in Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 200 shares during the period. Institutional investors own 93.61% of the company’s stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Several plaintiff firms and alert services (ClaimsFiler, Kaplan Fox, Bronstein Gewirtz, Schall, Glancy, Pomerantz, Rosen, etc.) remind investors of the April 21 lead‑plaintiff deadline and encourage affected shareholders to contact counsel; these notices increase publicity and bring more potential claimants into the case. ClaimsFiler Alert
• Neutral Sentiment: Multiple firms issued nearly identical deadline alerts over the last 48 hours (Kaplan Fox, Hagens Berman, Schall, Rosen, Glancy, Pomerantz), consolidating media attention around the litigation and the specified class period (Oct 31, 2024–Dec 30, 2025). Kaplan Fox / Globe & Mail
• Negative Sentiment: A plaintiff firm (Hagens Berman) highlights allegations the company made misstatements concerning FDA data — the complaint ties the suit to regulatory setbacks, which, if proven, could support larger investor claims and potential damages. This raises the prospect of material exposure beyond legal fees. Hagens Berman Alert
• Negative Sentiment: At least one alert frames the securities suit as following an FDA rejection and a recent federal court patent loss, signaling multiple catalysts behind investor claims (regulatory and IP setbacks increase downside risk to future revenues). Such combined regulatory/IP exposure typically amplifies potential settlement sizes and investor concern. GlobeNewswire / Hagens Berman
• Negative Sentiment: Coverage notes the original securities complaint was filed in February 2026; continued media and firm outreach suggests the litigation will remain an active headline risk through the April deadline and into any lead‑plaintiff selection, potentially affecting trading sentiment and valuation multiples. TipRanks summary

Corcept Therapeutics Price Performance

Shares of CORT opened at $42.49 on Friday. The firm has a market cap of $4.52 billion, a P/E ratio of 51.82 and a beta of 0.25. The stock has a 50 day simple moving average of $37.80 and a two-hundred day simple moving average of $59.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $91.00.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The company’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the business posted $0.26 earnings per share. On average, analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Insider Activity at Corcept Therapeutics

In related news, CEO Joseph K. Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total value of $1,311,733.86. Following the transaction, the chief executive officer owned 2,918,326 shares in the company, valued at $146,120,582.82. This trade represents a 0.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director G Leonard Baker, Jr. purchased 100,000 shares of the stock in a transaction on Tuesday, March 17th. The stock was acquired at an average cost of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the purchase, the director directly owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. The trade was a 9.55% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have sold 86,198 shares of company stock valued at $3,552,769. Insiders own 20.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on CORT. UBS Group started coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. HC Wainwright dropped their price objective on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Canaccord Genuity Group upped their target price on Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Finally, Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $77.67.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.